Bayerische Motoren Werke ADR (BMWYY)
29.20
+0.00 (0.00%)
OP · Last Trade: Jun 4th, 3:47 AM EDT
Detailed Quote
| Previous Close | 29.20 |
|---|---|
| Open | - |
| Bid | - |
| Ask | - |
| Day's Range | N/A - N/A |
| 52 Week Range | 25.15 - 34.07 |
| Volume | 0 |
| Market Cap | - |
| PE Ratio (TTM) | - |
| EPS (TTM) | - |
| Dividend & Yield | N/A (N/A) |
| 1 Month Average Volume | - |
Chart
News & Press Releases
Study Finds That Kids, Young People Wait Longer to Receive a Cancer Diagnosis
A recent study conducted by experts based at University of Nottingham in the UK has revealed that young individuals afflicted by certain kinds of cancer like bone malignancies take longer before being diagnosed .
Via Investor Brand Network · June 3, 2025
BioMedNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) to Present at Noble Capital Markets Emerging Growth Virtual Conference
Nutriband (NASDAQ: NTRB) announced that CEO Gareth Sheridan will present at Noble Capital Markets’ Emerging Growth Virtual Equity Conference on Thursday, June 5 at 4 p.m. ET. The session will feature a fireside-style Q&A open to live audience questions, with 1×1 meetings available for qualified investors. A webcast of the presentation will be accessible post-event on Nutriband’s website and Channelchek.com, where it will remain archived for 90 days.
Via Investor Brand Network · June 3, 2025
BioMedNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Posts Record Q1 Revenue, Advances AVERSA Fentanyl Development
Nutriband (NASDAQ: NTRB) reported first-quarter revenue of $667,000, a 63% year-over-year increase driven by expanded kinesiology tape production through its Pocono Pharma subsidiary and growing retail presence at Target, Walmart, Walgreens, and CVS. The company continues to prioritize shareholder value by scaling Pocono’s output through penetration pricing strategies while advancing development of AVERSA Fentanyl, an abuse-deterrent transdermal opioid patch. A newly formalized partnership with Kindeva Drug Delivery will support shared development costs in exchange for milestone payments as AVERSA moves toward regulatory approval. The product is projected to reach peak U.S. sales of $80 million to $200 million annually.
Via Investor Brand Network · June 2, 2025
Solutions to serious problems are always marketable, even if the overall economy isn't quite firing on all cylinders.
Via The Motley Fool · May 31, 2025
Riding Russia’s Edge: Ksyusha’s Pro Training for the EXTREME Adventure
Before embarking on the thrilling EXTREME Russia expedition with QJMOTOR and Benelli, Ksyusha, the adventurous rider, sought expert guidance to ensure a safe and exhilarating journey. She received a meticulous pro briefing from Evgeny Pyatigorsky, the esteemed Chief Instructor of BMW Motorrad Russia and a seasoned expert in the grueling Silk Way Rally. With decades of experience navigating extreme terrains and a reputation for training elite riders, Pyatigorsky’s insights were invaluable in preparing Ksyusha for the challenges ahead.
Via AB Newswire · May 30, 2025
Study Links Autism to Increased Risk of Developing Parkinson’s Disease
A recently conducted study by a team at Karolinska Institutet in Sweden has established a link between a diagnosis of autism spectrum disorder (ASD) to a heightened risk of Parkinson’s disease (PD). The research appeared in the journal JAMA Neurology . The research team believes the two conditions may share a number of underlying biological mechanisms.
Via Investor Brand Network · May 30, 2025
BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Reports Q1 Revenue Growth Driven by CDMO Contracts, Net Loss Narrows
Scinai Immunotherapeutics (NASDAQ: SCNI) reported first quarter 2025 financial results, posting $586K in revenue, up from zero in the prior-year period, reflecting continued expansion of its CDMO business. R&D expenses declined to $1.3M from $1.6M, while marketing, general and administrative costs held steady at $500K. The company recorded a $1.6M net loss, improving from a $2.2M loss in Q1 2024, aided by reduced R&D and financial expenses. Cash and equivalents totaled $1M at quarter-end, down from $2M a year earlier.
Via Investor Brand Network · May 30, 2025
Alzamend Neuro (NASDAQ: ALZN) is a clinical-stage biopharmaceutical company tackling some of the most pressing neurological and psychiatric conditions of our time — including Alzheimer’s disease, Bipolar Disorder (BD), Major Depressive Disorder (MDD), and Post-Traumatic Stress Disorder (PTSD). With a mission to “Make Alzheimer’s Just a Memory,” the Atlanta-based company is advancing a robust pipeline of therapies aimed at delivering long-overdue innovation in safety, efficacy, and tolerability. Rather than tweaking existing treatments, Alzamend is engineering bold new approaches that directly address the limitations of current standards of care.
Via Investor Brand Network · May 29, 2025
University of Houston Gets $3M to Establish Biomarker Core for Cancer Immunotherapy
Texas’ Cancer Prevention & Research Institute has awarded $3 million to the University of Houston to establish a biomarker core for cancer immunotherapy. The research institute has earned a reputation for funding research projects which are groundbreaking. The $3m is a fraction of its $93m total package earmarked for awarding grants to entities within the state.
Via Investor Brand Network · May 29, 2025
The automakers are hoping for a deal in June, a source told Reuters, while noting that it would rely on the companies pledging substantial investment in the U.S. to convince the administration.
Via Stocktwits · May 28, 2025
Gilston, QLD () May 28, 2025 -- Paradise Car Keys’s specialized services for luxury brands include EEPROM programming, ignition repairs, and advanced diagnostics.
Via Prodigy · May 28, 2025
House Approves Reconciliation Bill, Health Insurance and Medicaid to Be Impacted
On May 22, the U.S. House of Representatives approved the reconciliation bill for the 2025 budget with a one-vote difference between those in support of the bill and those opposed to it. The American Hospital Association says this legislation is going to have notable impacts upon healthcare insurance and Medicaid.
Via Investor Brand Network · May 28, 2025
BioMedNewsBreaks — TransCode Therapeutics, Inc. (NASDAQ: RNAZ) Appoints RNAi Pioneer Phillip Zamore to Scientific Advisory Board
TransCode Therapeutics (NASDAQ: RNAZ), has appointed Dr. Phillip D. Zamore, a leading figure in RNA interference (RNAi) research and co-founder of Alnylam Pharmaceuticals, to its Scientific Advisory Board. Dr. Zamore, currently Chair of the RNA Therapeutics Institute at UMass Chan Medical School, is renowned for his foundational work in RNA biology and gene silencing mechanisms. His election to the National Academy of Sciences and other prestigious institutions underscores his impact on the field. TransCode leaders praised the addition as a strategic enhancement to the company’s RNA-targeted cancer therapy programs.
Via Investor Brand Network · May 28, 2025
BioMedNewsBreaks — Oragenics Inc. (NYSE American: OGEN) Sets 1-for-30 Reverse Stock Split Effective June 3
Oragenics (NYSE American: OGEN) announced that its board has approved a 1-for-30 reverse stock split of its common shares, effective June 3, 2025. The move consolidates every 30 shares into one and aims to boost the company’s share price and appeal to long-term investors. Shares will begin trading on a split-adjusted basis under the existing symbol “OGEN” with a new CUSIP number. CEO Janet Huffman stated the action aligns with Oragenics’ strategy to enhance its capital markets profile while advancing treatments for brain-related health conditions.
Via Investor Brand Network · May 28, 2025
New Swallowable Pill Provides Real-Time Gut Inflammation Tracking
The GI tract and its components like the mucosal lining play an important role of preventing harmful substances from finding their way into the bloodstream. When this mucosal lining is compromised, serious consequences like the entry of undigested food, toxins and bacteria into the bloodstream result. “Leaky gut” is responsible for conditions like inflammatory bowel disease.
Via Investor Brand Network · May 27, 2025
While U.S. markets remained closed Monday for Memorial Day, European equities surged after President Donald Trump agreed to delay a planned 50% tariff on European Union imports, easing investor concerns and reviving risk appetite.
Via Benzinga · May 26, 2025
Whop's study reveals one-third of Gen Z consumers regularly make purchases based on AI-generated influencer recommendations, highlighting AI influencers' rising trust and influence among young consumers on social media platforms.
Via Press Release Distribution Service · May 23, 2025
While startup headlines are often dominated by moonshot valuations and flashy funding rounds, there's a consultancy quietly turning raw potential into real money — and doing it with ruthless precision.
Via AB Newswire · May 23, 2025
Soligenix Inc. (NASDAQ: SNGX) Innovative Treatment to Combat Bacterial Infection Fills Urgent Need for Alternatives to Antibiotics
In the face of escalating antibiotic resistance, the medical community is urgently seeking alternative treatments for bacterial infections. Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company, is at the forefront of this effort with its development of SGX943 (dusquetide), a novel broad-spectrum therapy designed to combat bacterial infections without relying on traditional antibiotics.
Via Investor Brand Network · May 23, 2025
Intelligent Bio Solutions Inc. (NASDAQ: INBS) Progressing with FDA Clearance for Fingerprint Drug Testing as Global Demand Grows
Intelligent Bio Solutions (NASDAQ: INBS), a medical technology company specializing in rapid, non-invasive testing solutions, is preparing for its expected U.S. launch in 2025, as it is progressing through the FDA clearance process for its Intelligent Fingerprinting Drug Screening System. The non-invasive device, which detects recent drug use via fingerprint sweat, is gaining international traction for its speed, portability, and ability to integrate into a range of safety-critical environments.
Via Investor Brand Network · May 23, 2025
European stocks tumbled after President Trump threatened a 50% tariff on EU imports starting June 1, targeting a $250 billion trade deficit.
Via Benzinga · May 23, 2025
Nutriband Inc. (NASDAQ: NTRB) Charts Path to Commercialization
In a recent report to shareholders, Nutriband (NASDAQ: NTRB) CEO Gareth Sheridan shared significant company achievements and milestones as well as his expectations for 2025 ( https://ibn.fm/9K5zT ). At the center of the company’s positive outlook for future is noteworthy progress made toward the commercialization of its proprietary Aversa technology, including a strong partnership with Kindeva Drug Delivery.
Via Investor Brand Network · May 22, 2025
Experts Say New Test for Brain Tumors is a Game-Changer
Researchers have developed a novel brain tumor test that surgical experts have dubbed a game changer. This is because the test collapses the needed time to obtain an accurate diagnosis to just hours rather than multiple weeks as has been the case.
Via Investor Brand Network · May 22, 2025